According to A Latest intelligence report published by Market IntelliX, the global market for Oligonucleotide Therapeutics Drug should grow from US$ million in 2022 to US$ million by 2029, with a CAGR of % for the period of 2023-2029.
China Oligonucleotide Therapeutics Drug market should grow from US$ million in 2022 to US$ million by 2029, with a CAGR of % for the period of 2023-2029.
The United States Oligonucleotide Therapeutics Drug market should grow from US$ million in 2022 to US$ million by 2029, with a CAGR of % for the period of 2023-2029.
In terms of type, Antisense Oligonucleotide segment holds a share about % in 2022 and will reach % in 2029; while in terms of application, Neuromuscular Diseases has a share approximately % in 2022 and will grow at a CAGR % during 2023 and 2029.
The global key manufacturers of Oligonucleotide Therapeutics Drug include Biogen, Sarepta Therapeutics, Jazz Pharmaceuticals, Bausch & Lomb, Alnylam Pharmaceuticals, Dynavax Technologies, Kastle therapeutics and Akcea Therapeutics, etc. In 2022, the global top five players hold a share approximately % in terms of revenue.
Many pharmaceutical companies were conducting research on oligonucleotide therapy, which employs chemically synthesized nucleotide-like small molecule drugs with potential specificity similar to that of therapeutic antibodies.
This report aims to provide a comprehensive study of the global market for Oligonucleotide Therapeutics Drug. Report Highlights:
(1) Global Oligonucleotide Therapeutics Drug market size (value), history data from 2018-2022 and forecast data from 2023 to 2029.
(2) Global Oligonucleotide Therapeutics Drug market competitive situation, revenue and market share, from 2018 to 2022.
(3) China Oligonucleotide Therapeutics Drug market competitive situation, revenue and market share, from 2018 to 2022.
(4) Global Oligonucleotide Therapeutics Drug segment by region (or country), key regions cover the United States, Europe, Japan, South Korea, Southeast Asia and India, etc.
(5) Global Oligonucleotide Therapeutics Drug segment by type and by application and regional segment by type and by application.
(6) Oligonucleotide Therapeutics Drug industry supply chain, upstream, midstream and downstream analysis.
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa
Market segment by type, covers
Antisense Oligonucleotide
Aptamer
Other
Market segment by application, can be divided into
Neuromuscular Diseases
ATTR
Hepatic VOD
Other
Market segment by players, this report covers
Biogen
Sarepta Therapeutics
Jazz Pharmaceuticals
Bausch & Lomb
Alnylam Pharmaceuticals
Dynavax Technologies
Kastle therapeutics
Akcea Therapeutics
1 Market Overview
1.1 Product Overview and Scope of Oligonucleotide Therapeutics Drug
1.2 Global Oligonucleotide Therapeutics Drug Market Size and Forecast
1.3 China Oligonucleotide Therapeutics Drug Market Size and Forecast
1.4 China Market Percentage in Global
1.4.1 By Revenue, China Oligonucleotide Therapeutics Drug Share in Global Market, 2018-2029
1.4.2 Oligonucleotide Therapeutics Drug Market Size: China VS Global, 2018-2029
1.5 Oligonucleotide Therapeutics Drug Market Dynamics
1.5.1 Oligonucleotide Therapeutics Drug Market Drivers
1.5.2 Oligonucleotide Therapeutics Drug Market Restraints
1.5.3 Oligonucleotide Therapeutics Drug Industry Trends
1.5.4 Oligonucleotide Therapeutics Drug Industry Policy
2 Global Competitive Situation by Company
2.1 Global Oligonucleotide Therapeutics Drug Revenue by Company (2018-2023)
2.2 Global Oligonucleotide Therapeutics Drug Participants, Market Position (Tier 1, Tier 2 and Tier 3)
2.3 Global Oligonucleotide Therapeutics Drug Concentration Ratio
2.4 Global Oligonucleotide Therapeutics Drug Mergers & Acquisitions, Expansion Plans
2.5 Global Oligonucleotide Therapeutics Drug Manufacturers Product Type
3 China Competitive Situation by Company
3.1 China Oligonucleotide Therapeutics Drug Revenue by Company (2018-2023)
3.2 China Oligonucleotide Therapeutics Drug Oligonucleotide Therapeutics Drug Participants, Market Position (Tier 1, Tier 2 and Tier 3)
3.3 China Oligonucleotide Therapeutics Drug, Revenue Percentage of Local Players VS Foreign Manufacturers (2018-2023)
4 Industry Chain Analysis
4.1 Oligonucleotide Therapeutics Drug Industry Chain
4.2 Oligonucleotide Therapeutics Drug Upstream Analysis
4.3 Oligonucleotide Therapeutics Drug Midstream Analysis
4.4 Oligonucleotide Therapeutics Drug Downstream Analysis
5 Sights by Type
5.1 Oligonucleotide Therapeutics Drug Classification
5.1.1 Antisense Oligonucleotide
5.1.2 Aptamer
5.1.3 Other
5.2 By Type, Global Oligonucleotide Therapeutics Drug Market Size & CAGR, 2018 VS 2022 VS 2029
5.3 By Type, Global Oligonucleotide Therapeutics Drug Revenue, 2018-2029
6 Sights by Application
6.1 Oligonucleotide Therapeutics Drug Segment by Application
6.1.1 Neuromuscular Diseases
6.1.2 ATTR
6.1.3 Hepatic VOD
6.1.4 Other
6.2 By Application, Global Oligonucleotide Therapeutics Drug Market Size & CAGR, 2018 VS 2022 VS 2029
6.3 By Application, Global Oligonucleotide Therapeutics Drug Revenue, 2018-2029
7 Sales Sights by Region
7.1 By Region, Global Oligonucleotide Therapeutics Drug Market Size, 2018 VS 2022 VS 2029
7.2 By Region, Global Oligonucleotide Therapeutics Drug Market Size, 2018-2029
7.3 North America
7.3.1 North America Oligonucleotide Therapeutics Drug Market Size & Forecasts, 2018-2029
7.3.2 By Country, North America Oligonucleotide Therapeutics Drug Market Size Market Share
7.4 Europe
7.4.1 Europe Oligonucleotide Therapeutics Drug Market Size & Forecasts, 2018-2029
7.4.2 By Country, Europe Oligonucleotide Therapeutics Drug Market Size Market Share
7.5 Asia Pacific
7.5.1 Asia Pacific Oligonucleotide Therapeutics Drug Market Size & Forecasts, 2018-2029
7.5.2 By Country/Region, Asia Pacific Oligonucleotide Therapeutics Drug Market Size Market Share
7.6 South America
7.6.1 South America Oligonucleotide Therapeutics Drug Market Size & Forecasts, 2018-2029
7.6.2 By Country, South America Oligonucleotide Therapeutics Drug Market Size Market Share
7.7 Middle East & Africa
8 Sights by Country Level
8.1 By Country, Global Oligonucleotide Therapeutics Drug Market Size & CAGR,2018 VS 2022 VS 2029
8.2 By Country, Global Oligonucleotide Therapeutics Drug Market Size, 2018-2029
8.3 U.S.
8.3.1 U.S. Oligonucleotide Therapeutics Drug Market Size, 2018-2029
8.3.2 By Company, U.S. Oligonucleotide Therapeutics Drug Revenue Market Share, 2018-2023
8.3.3 By Type, U.S. Oligonucleotide Therapeutics Drug Revenue Market Share, 2022 VS 2029
8.3.4 By Application, U.S. Oligonucleotide Therapeutics Drug Revenue Market Share, 2022 VS 2029
8.4 Europe
8.4.1 Europe Oligonucleotide Therapeutics Drug Market Size, 2018-2029
8.4.2 By Company, Europe Oligonucleotide Therapeutics Drug Revenue Market Share, 2018-2023
8.4.3 By Type, Europe Oligonucleotide Therapeutics Drug Revenue Market Share, 2022 VS 2029
8.4.4 By Application, Europe Oligonucleotide Therapeutics Drug Revenue Market Share, 2022 VS 2029
8.5 China
8.5.1 China Oligonucleotide Therapeutics Drug Market Size, 2018-2029
8.5.2 By Company, China Oligonucleotide Therapeutics Drug Revenue Market Share, 2018-2023
8.5.3 By Type, China Oligonucleotide Therapeutics Drug Revenue Market Share, 2022 VS 2029
8.5.4 By Application, China Oligonucleotide Therapeutics Drug Revenue Market Share, 2022 VS 2029
8.6 Japan
8.6.1 Japan Oligonucleotide Therapeutics Drug Market Size, 2018-2029
8.6.2 By Company, Japan Oligonucleotide Therapeutics Drug Revenue Market Share, 2018-2023
8.6.3 By Type, Japan Oligonucleotide Therapeutics Drug Revenue Market Share, 2022 VS 2029
8.6.4 By Application, Japan Oligonucleotide Therapeutics Drug Revenue Market Share, 2022 VS 2029
8.7 South Korea
8.7.1 South Korea Oligonucleotide Therapeutics Drug Market Size, 2018-2029
8.7.2 By Company, South Korea Oligonucleotide Therapeutics Drug Revenue Market Share, 2018-2023
8.7.3 By Type, South Korea Oligonucleotide Therapeutics Drug Revenue Market Share, 2022 VS 2029
8.7.4 By Application, South Korea Oligonucleotide Therapeutics Drug Revenue Market Share, 2022 VS 2029
8.8 Southeast Asia
8.8.1 Southeast Asia Oligonucleotide Therapeutics Drug Market Size, 2018-2029
8.8.2 By Company, Southeast Asia Oligonucleotide Therapeutics Drug Revenue Market Share, 2018-2023
8.8.3 By Type, Southeast Asia Oligonucleotide Therapeutics Drug Revenue Market Share, 2022 VS 2029
8.8.4 By Application, Southeast Asia Oligonucleotide Therapeutics Drug Revenue Market Share, 2022 VS 2029
8.9 India
8.9.1 India Oligonucleotide Therapeutics Drug Market Size, 2018-2029
8.9.2 By Company, India Oligonucleotide Therapeutics Drug Revenue Market Share, 2018-2023
8.9.3 By Type, India Oligonucleotide Therapeutics Drug Revenue Market Share, 2022 VS 2029
8.9.4 By Application, India Oligonucleotide Therapeutics Drug Revenue Market Share, 2022 VS 2029
8.10 Middle East & Asia
8.10.1 Middle East & Asia Oligonucleotide Therapeutics Drug Market Size, 2018-2029
8.10.2 By Company, Middle East & Asia Oligonucleotide Therapeutics Drug Revenue Market Share, 2018-2023
8.10.3 By Type, Middle East & Asia Oligonucleotide Therapeutics Drug Revenue Market Share, 2022 VS 2029
8.10.4 By Application, Middle East & Asia Oligonucleotide Therapeutics Drug Revenue Market Share, 2022 VS 2029
9 Global Manufacturers Profile
9.1 Biogen
9.1.1 Biogen Company Information, Head Office, Market Area and Industry Position
9.1.2 Biogen Company Profile and Main Business
9.1.3 Biogen Oligonucleotide Therapeutics Drug Models, Specifications and Application
9.1.4 Biogen Oligonucleotide Therapeutics Drug Revenue and Gross Margin, 2018-2023
9.1.5 Biogen Recent Developments
9.2 Sarepta Therapeutics
9.2.1 Sarepta Therapeutics Company Information, Head Office, Market Area and Industry Position
9.2.2 Sarepta Therapeutics Company Profile and Main Business
9.2.3 Sarepta Therapeutics Oligonucleotide Therapeutics Drug Models, Specifications and Application
9.2.4 Sarepta Therapeutics Oligonucleotide Therapeutics Drug Revenue and Gross Margin, 2018-2023
9.2.5 Sarepta Therapeutics Recent Developments
9.3 Jazz Pharmaceuticals
9.3.1 Jazz Pharmaceuticals Company Information, Head Office, Market Area and Industry Position
9.3.2 Jazz Pharmaceuticals Company Profile and Main Business
9.3.3 Jazz Pharmaceuticals Oligonucleotide Therapeutics Drug Models, Specifications and Application
9.3.4 Jazz Pharmaceuticals Oligonucleotide Therapeutics Drug Revenue and Gross Margin, 2018-2023
9.3.5 Jazz Pharmaceuticals Recent Developments
9.4 Bausch & Lomb
9.4.1 Bausch & Lomb Company Information, Head Office, Market Area and Industry Position
9.4.2 Bausch & Lomb Company Profile and Main Business
9.4.3 Bausch & Lomb Oligonucleotide Therapeutics Drug Models, Specifications and Application
9.4.4 Bausch & Lomb Oligonucleotide Therapeutics Drug Revenue and Gross Margin, 2018-2023
9.4.5 Bausch & Lomb Recent Developments
9.5 Alnylam Pharmaceuticals
9.5.1 Alnylam Pharmaceuticals Company Information, Head Office, Market Area and Industry Position
9.5.2 Alnylam Pharmaceuticals Company Profile and Main Business
9.5.3 Alnylam Pharmaceuticals Oligonucleotide Therapeutics Drug Models, Specifications and Application
9.5.4 Alnylam Pharmaceuticals Oligonucleotide Therapeutics Drug Revenue and Gross Margin, 2018-2023
9.5.5 Alnylam Pharmaceuticals Recent Developments
9.6 Dynavax Technologies
9.6.1 Dynavax Technologies Company Information, Head Office, Market Area and Industry Position
9.6.2 Dynavax Technologies Company Profile and Main Business
9.6.3 Dynavax Technologies Oligonucleotide Therapeutics Drug Models, Specifications and Application
9.6.4 Dynavax Technologies Oligonucleotide Therapeutics Drug Revenue and Gross Margin, 2018-2023
9.6.5 Dynavax Technologies Recent Developments
9.7 Kastle therapeutics
9.7.1 Kastle therapeutics Company Information, Head Office, Market Area and Industry Position
9.7.2 Kastle therapeutics Company Profile and Main Business
9.7.3 Kastle therapeutics Oligonucleotide Therapeutics Drug Models, Specifications and Application
9.7.4 Kastle therapeutics Oligonucleotide Therapeutics Drug Revenue and Gross Margin, 2018-2023
9.7.5 Kastle therapeutics Recent Developments
9.8 Akcea Therapeutics
9.8.1 Akcea Therapeutics Company Information, Head Office, Market Area and Industry Position
9.8.2 Akcea Therapeutics Company Profile and Main Business
9.8.3 Akcea Therapeutics Oligonucleotide Therapeutics Drug Models, Specifications and Application
9.8.4 Akcea Therapeutics Oligonucleotide Therapeutics Drug Revenue and Gross Margin, 2018-2023
9.8.5 Akcea Therapeutics Recent Developments
10 Conclusion
11 Appendix
11.1 Research Methodology
11.2 Data Source
11.2.1 Secondary Sources
11.2.2 Primary Sources
11.3 Market Estimation Model
11.4 Disclaimer
Table 1. Oligonucleotide Therapeutics Drug Market Size & CAGR: China VS Global, (US$ Million), 2018-2029
Table 2. Oligonucleotide Therapeutics Drug Market Restraints
Table 3. Oligonucleotide Therapeutics Drug Market Trends
Table 4. Oligonucleotide Therapeutics Drug Industry Policy
Table 5. Global Oligonucleotide Therapeutics Drug Revenue by Company (2018-2023) & (US$ million)
Table 6. Global Oligonucleotide Therapeutics Drug Revenue Market Share by Company (2018-2023)
Table 7. Global Oligonucleotide Therapeutics Drug Manufacturers Market Concentration Ratio (CR3 and HHI)
Table 8. Global Oligonucleotide Therapeutics Drug Mergers & Acquisitions, Expansion Plans
Table 9. Global Oligonucleotide Therapeutics Drug Manufacturers Product Type
Table 10. China Oligonucleotide Therapeutics Drug Revenue by Company (2018-2023) & (US$ million)
Table 11. China Oligonucleotide Therapeutics Drug Revenue Market Share by Company (2018-2023)
Table 12. Global Key Players of Oligonucleotide Therapeutics Drug Upstream (Raw Materials)
Table 13. Global Oligonucleotide Therapeutics Drug Typical Customers
Table 14. Oligonucleotide Therapeutics Drug Typical Distributors
Table 15. By Type, Global Oligonucleotide Therapeutics Drug Revenue & CAGR, 2018 VS 2022 VS 2029, US$ Million
Table 16. By Application, Global Oligonucleotide Therapeutics Drug Revenue & CAGR, 2018 VS 2022 VS 2029, US$ Million
Table 17. By Region, Global Oligonucleotide Therapeutics Drug Market Size, 2018 VS 2022 VS 2029, US$ Million
Table 18. By Region, Global Oligonucleotide Therapeutics Drug Revenue, 2018-2029, US$ Million
Table 19. By Country, Global Oligonucleotide Therapeutics Drug Revenue & CAGR,2018 VS 2022 VS 2029, US$ Million
Table 20. By Country, Global Oligonucleotide Therapeutics Drug Revenue, 2018-2029, US$ Million
Table 21. By Country, Global Oligonucleotide Therapeutics Drug Revenue Market Share, 2018-2029
Table 22. Biogen Company Information, Head Office, Market Area and Industry Position
Table 23. Biogen Company Profile and Main Business
Table 24. Biogen Oligonucleotide Therapeutics Drug Models, Specifications and Application
Table 25. Biogen Oligonucleotide Therapeutics Drug Revenue and Gross Margin, 2018-2023
Table 26. Biogen Recent Developments
Table 27. Sarepta Therapeutics Company Information, Head Office, Market Area and Industry Position
Table 28. Sarepta Therapeutics Company Profile and Main Business
Table 29. Sarepta Therapeutics Oligonucleotide Therapeutics Drug Models, Specifications and Application
Table 30. Sarepta Therapeutics Oligonucleotide Therapeutics Drug Revenue and Gross Margin, 2018-2023
Table 31. Sarepta Therapeutics Recent Developments
Table 32. Jazz Pharmaceuticals Company Information, Head Office, Market Area and Industry Position
Table 33. Jazz Pharmaceuticals Company Profile and Main Business
Table 34. Jazz Pharmaceuticals Oligonucleotide Therapeutics Drug Models, Specifications and Application
Table 35. Jazz Pharmaceuticals Oligonucleotide Therapeutics Drug Revenue and Gross Margin, 2018-2023
Table 36. Jazz Pharmaceuticals Recent Developments
Table 37. Bausch & Lomb Company Information, Head Office, Market Area and Industry Position
Table 38. Bausch & Lomb Company Profile and Main Business
Table 39. Bausch & Lomb Oligonucleotide Therapeutics Drug Models, Specifications and Application
Table 40. Bausch & Lomb Oligonucleotide Therapeutics Drug Revenue and Gross Margin, 2018-2023
Table 41. Bausch & Lomb Recent Developments
Table 42. Alnylam Pharmaceuticals Company Information, Head Office, Market Area and Industry Position
Table 43. Alnylam Pharmaceuticals Company Profile and Main Business
Table 44. Alnylam Pharmaceuticals Oligonucleotide Therapeutics Drug Models, Specifications and Application
Table 45. Alnylam Pharmaceuticals Oligonucleotide Therapeutics Drug Revenue and Gross Margin, 2018-2023
Table 46. Alnylam Pharmaceuticals Recent Developments
Table 47. Dynavax Technologies Company Information, Head Office, Market Area and Industry Position
Table 48. Dynavax Technologies Company Profile and Main Business
Table 49. Dynavax Technologies Oligonucleotide Therapeutics Drug Models, Specifications and Application
Table 50. Dynavax Technologies Oligonucleotide Therapeutics Drug Revenue and Gross Margin, 2018-2023
Table 51. Dynavax Technologies Recent Developments
Table 52. Kastle therapeutics Company Information, Head Office, Market Area and Industry Position
Table 53. Kastle therapeutics Company Profile and Main Business
Table 54. Kastle therapeutics Oligonucleotide Therapeutics Drug Models, Specifications and Application
Table 55. Kastle therapeutics Oligonucleotide Therapeutics Drug Revenue and Gross Margin, 2018-2023
Table 56. Kastle therapeutics Recent Developments
Table 57. Akcea Therapeutics Company Information, Head Office, Market Area and Industry Position
Table 58. Akcea Therapeutics Company Profile and Main Business
Table 59. Akcea Therapeutics Oligonucleotide Therapeutics Drug Models, Specifications and Application
Table 60. Akcea Therapeutics Oligonucleotide Therapeutics Drug Revenue and Gross Margin, 2018-2023
Table 61. Akcea Therapeutics Recent Developments
List of Figure
Figure 1. Oligonucleotide Therapeutics Drug Picture
Figure 2. Global Oligonucleotide Therapeutics Drug Industry Market Size and Forecast (US$ million) & (2018-2029)
Figure 3. China Oligonucleotide Therapeutics Drug Revenue and Forecast (US$ million) & (2018-2029)
Figure 4. 2018-2029 China Oligonucleotide Therapeutics Drug Market Share of Global
Figure 5. Global Oligonucleotide Therapeutics Drug Key Participants, Market Share, 2021 VS 2022 VS 2023
Figure 6. Global Oligonucleotide Therapeutics Drug Market Share by Company, (Tier 1, Tier 2 and Tier 3), 2018-2023
Figure 7. China Oligonucleotide Therapeutics Drug Key Participants, Market Share, 2021 VS 2022 VS 2023
Figure 8. China Oligonucleotide Therapeutics Drug Revenue, Domestic VS Import Products, Proportion of China Local Players and Foreign Players, 2018-2023
Figure 9. Oligonucleotide Therapeutics Drug Industry Chain
Figure 10. Antisense Oligonucleotide
Figure 11. Aptamer
Figure 12. Other
Figure 13. By Type, Global Oligonucleotide Therapeutics Drug Revenue, 2018-2029, US$ Million
Figure 14. By Type, Global Oligonucleotide Therapeutics Drug Revenue Market Share, 2018-2029
Figure 15. Neuromuscular Diseases
Figure 16. ATTR
Figure 17. Hepatic VOD
Figure 18. Other
Figure 19. By Application, Global Oligonucleotide Therapeutics Drug Revenue, 2018-2029, US$ Million
Figure 20. By Application, Global Oligonucleotide Therapeutics Drug Revenue Market Share, 2018-2029
Figure 21. By Region, Global Oligonucleotide Therapeutics Drug Revenue Market Share, 2018-2029
Figure 22. North America Oligonucleotide Therapeutics Drug Revenue & Forecasts, 2018-2029, US$ Million
Figure 23. By Country, North America Oligonucleotide Therapeutics Drug Revenue Market Share, 2018-2023
Figure 24. Europe Oligonucleotide Therapeutics Drug Revenue & Forecasts, 2018-2029, US$ Million
Figure 25. By Country, Europe Oligonucleotide Therapeutics Drug Revenue Market Share, 2018-2023
Figure 26. Asia Pacific Oligonucleotide Therapeutics Drug Revenue & Forecasts, 2018-2029, US$ Million
Figure 27. By Country/Region, Asia Pacific Oligonucleotide Therapeutics Drug Revenue Market Share, 2018-2023
Figure 28. South America Oligonucleotide Therapeutics Drug Revenue & Forecasts, 2018-2029, US$ Million
Figure 29. By Country, South America Oligonucleotide Therapeutics Drug Revenue Market Share, 2018-2023
Figure 30. Middle East & Africa Oligonucleotide Therapeutics Drug Revenue & Forecasts, 2018-2029, US$ Million
Figure 31. U.S. Oligonucleotide Therapeutics Drug Revenue, 2018-2029, (US$ Million)
Figure 32. By Company, U.S. Oligonucleotide Therapeutics Drug Market Share, 2018-2023
Figure 33. By Type, U.S. Oligonucleotide Therapeutics Drug Revenue Market Share, 2022 VS 2029
Figure 34. By Application, U.S. Oligonucleotide Therapeutics Drug Revenue Market Share, 2022 VS 2029
Figure 35. Europe Oligonucleotide Therapeutics Drug Revenue, 2018-2029, (US$ Million)
Figure 36. By Company, Europe Oligonucleotide Therapeutics Drug Market Share, 2018-2023
Figure 37. By Type, Europe Oligonucleotide Therapeutics Drug Revenue Market Share, 2022 VS 2029
Figure 38. By Application, Europe Oligonucleotide Therapeutics Drug Revenue Market Share, 2022 VS 2029
Figure 39. China Oligonucleotide Therapeutics Drug Revenue, 2018-2029, (US$ Million)
Figure 40. By Company, China Oligonucleotide Therapeutics Drug Market Share, 2018-2023
Figure 41. By Type, China Oligonucleotide Therapeutics Drug Revenue Market Share, 2022 VS 2029
Figure 42. By Application, China Oligonucleotide Therapeutics Drug Revenue Market Share, 2022 VS 2029
Figure 43. Japan Oligonucleotide Therapeutics Drug Revenue, 2018-2029, (US$ Million)
Figure 44. By Company, Japan Oligonucleotide Therapeutics Drug Market Share, 2018-2023
Figure 45. By Type, Japan Oligonucleotide Therapeutics Drug Revenue Market Share, 2022 VS 2029
Figure 46. By Application, Japan Oligonucleotide Therapeutics Drug Revenue Market Share, 2022 VS 2029
Figure 47. South Korea Oligonucleotide Therapeutics Drug Revenue, 2018-2029, (US$ Million)
Figure 48. By Company, South Korea Oligonucleotide Therapeutics Drug Market Share, 2018-2023
Figure 49. By Type, South Korea Oligonucleotide Therapeutics Drug Revenue Market Share, 2022 VS 2029
Figure 50. By Application, South Korea Oligonucleotide Therapeutics Drug Revenue Market Share, 2022 VS 2029
Figure 51. Southeast Asia Oligonucleotide Therapeutics Drug Revenue, 2018-2029, (US$ Million)
Figure 52. By Company, Southeast Asia Oligonucleotide Therapeutics Drug Market Share, 2018-2023
Figure 53. By Type, Southeast Asia Oligonucleotide Therapeutics Drug Revenue Market Share, 2022 VS 2029
Figure 54. By Application, Southeast Asia Oligonucleotide Therapeutics Drug Revenue Market Share, 2022 VS 2029
Figure 55. India Oligonucleotide Therapeutics Drug Revenue, 2018-2029, (US$ Million)
Figure 56. By Company, India Oligonucleotide Therapeutics Drug Market Share, 2018-2023
Figure 57. By Type, India Oligonucleotide Therapeutics Drug Revenue Market Share, 2022 VS 2029
Figure 58. By Application, India Oligonucleotide Therapeutics Drug Revenue Market Share, 2022 VS 2029
Figure 59. Middle East & Asia Oligonucleotide Therapeutics Drug Revenue, 2018-2029, (US$ Million)
Figure 60. By Company, Middle East & Asia Oligonucleotide Therapeutics Drug Market Share, 2018-2023
Figure 61. By Type, Middle East & Asia Oligonucleotide Therapeutics Drug Revenue Market Share, 2022 VS 2029
Figure 62. By Application, Middle East & Asia Oligonucleotide Therapeutics Drug Revenue Market Share, 2022 VS 2029
Figure 63. Research Methodology
Figure 64. Breakdown of Primary Interviews
Figure 65. Bottom-up Approaches
Figure 66. Top-down Approaches
Methodology/Research Approach
This research study involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.Research Programs/Design
Historical Data (2015-2019) |
|
|
Influencing Factors |
|
|
Market Forecast (2021-2026) |
|
|
Market Size Estimation
Top-down and bottom-up approaches are used to validate the global Voluntary Carbon Offset market size market and estimate the market size for Company, regions segments, product segments and Application (end users).
The market estimations in this report are based on the marketed sale price of Voluntary Carbon Offset (excluding any discounts provided by the player, distributor, wholesaler or traders). The percentage splits, market share, and breakdowns of the product segments are derived on the basis of weights assigned to each of the segments on the basis of their utilization rate and average sale price. The regional splits of the overall Voluntary Carbon Offset market and its sub-segments are based on the percentage adoption or utilization of the given product in the respective region or country.
Major Company in the market is identified through secondary research and their market revenues determined through primary and secondary research. Secondary research included the research of the annual and financial reports of the top Company; whereas, primary research included extensive interviews of key opinion leaders and industry experts such as experienced front-line staff, directors, CEOs and marketing executives. The percentage splits, market share, Growth Rate and breakdowns of the product markets are determined through using secondary sources and verified through the primary sources.
All possible factors that influence the markets included in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. The market size for top-level markets and sub-segments is normalized, and the effect of inflation, economic downturns, and regulatory & policy changes or other factors are not accounted for in the market forecast. This data is combined and added with detailed inputs and analysis from Market Intellix and presented in this report
The following figure shows an illustrative representation of the overall market size estimation process used for this study.
Market Breakdown and Data Triangulation
After complete market engineering with calculations for market statistics; market size estimations; market forecasting; market breakdown; and data triangulation, extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub-segments listed in this report. Extensive qualitative and further quantitative analysis is also done from all the numbers arrived at in the complete market engineering process to list key information throughout the report.
Data Source
Secondary Sources
Secondary sources include such as press releases, annual reports, non-profit organizations, industry associations, governmental agencies and customs data, etc. This research study involves the usage of widespread secondary sources, directories, databases such as Bloomberg Business, Wind Info, Hoovers, Factiva (Dow Jones & Company), and TRADING ECONOMICS, and News Network, statista, Federal Reserve Economic Data, annual reports, BIS Statistics, ICIS; company house documents; CAS(American Chemical Society); investor presentations; and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and Hospitals study of the Voluntary Carbon Offset market. It was also used to obtain important information about the top companies, market classification and segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives.
Market Size |
|
|
Market Position of Top Company |
|
|
Qualitative Analysis |
|
|
Primary Sources
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include product Company (and their competitors), opinion leaders, industry experts, research institutions, distributors, dealer and traders, as well as the raw materials suppliers and producers, etc.
The primary sources from the demand side include industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, end use (product buyers), and related key executives from various key companies and organizations operating in the global market.
Primary research was conducted to identify segmentation Type, product price range, product Application, key Company, raw materials supply and the downstream demand, industry status and outlook, and key market dynamics such as risks, influence factors, opportunities, market barriers, industry trends, and key player strategies.
Key Executives Interviewed
Key Data Information from Primary Sources
Primary Sources | Parameters | Key Data |
Market Segments(by Application, by Type) |
|
|
Total Market |
|
|